Shimada A, Kawasaki E, Abiru N, et al. Diagnostic Criteria of SPIDDM (2023). J Japan Diabetes Soc. 2023;66:587–91 ((In Japanese)).

Google Scholar 

Shimada A, Kawasaki E, Abiru N, et al. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version). Diabetol Int. 2024;15:1–4.

Article  PubMed  Google Scholar 

Shimada A, Kawasaki E, Abiru N, et al. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version). J Diabetes Investig. 2024;15:254–7.

Article  PubMed  PubMed Central  Google Scholar 

Tanaka S, Ohmori M, Awata T, et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus of the Japan Diabetes Society. Diabetol Int. 2015;6:1–7.

Article  Google Scholar 

Nishimura A, Matsumura K, Kikuno S, et al. Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives. Diabetes Metab Syndr Obes. 2019;12:2461–77.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yasui J, Kawasaki E, Tanaka S, et al. Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Clinical and Genetic Characteristics of Non-Insulin- Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. PLoS ONE. 2016;11:e0155643.

Article  PubMed  PubMed Central  Google Scholar 

Tanaka S, Awata T, Shimada A, et al. Clinical Characteristics of Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus (SPIDDM: 1st Subcommittee Report on SPIDDM, Committee on Type 1 Diabetes, Japan Diabetes Society and Committee on Type 1 Diabetes. J Japan Diab Soc. 2011;54:65–75 ((In Japanese)).

Google Scholar 

Kawasaki E. Anti-islet autoantibodies in type 1 diabetes. Int J Mol Sci. 2023;24:10012.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maruyama T, Tanaka S, Shimada A, et al. Insulin interven slowly J Clin Endocrinol Metab. 2008;93:2115–21.

Article  CAS  Google Scholar 

Buzzetti R, Tuomi T, Mauricio D, et al. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement. From Int Expert Panel Diabetes. 2020;69:2037–47.

CAS  Google Scholar 

Zachariah S, Sharfi MO, Nussey SS, et al. Latent autoimmune diabetes in the young. Clin Med (Lond). 2008;8:552–3.

Article  PubMed  CAS  Google Scholar 

Kawasaki E, Nakamura K, Kuriya G, et al. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. J Clin Endocrinol Metab. 2010;95:707–13.

Article  PubMed  CAS  Google Scholar 

Murao S, Kondo S, Ohashi J, et al. Anti-thyroid peroxidase antibody, IA-2 antibody, and fasting C-peptide levels predict beta cell failure in patients with latent autoimmune diabetes in adults (LADA)–a 5-year follow-up of the Ehime study. Diabetes Res Clin Pract. 2008;80:114–21.

Article  PubMed  CAS  Google Scholar 

Tanaka S, Okubo M, Nagasawa K, et al. Predictive value of titer of GAD antibodies for further progression of beta cell dysfunction in slowly progressive insulin-dependent (type 1) diabetes (SPIDDM). Diabetol Int. 2015;7:42–52.

Article  PubMed  PubMed Central  Google Scholar 

Wada E, Onoue T, Kinoshita T, et al. Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study. Diabetologia. 2021;64:2183–92.

Article  PubMed  CAS  Google Scholar 

Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospect Diabetes Study Group Lancet. 1997;350(9087):1288–93.

CAS  Google Scholar 

Johansen OE, Boehm BO, Grill V, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014;37:e11-12.

Article  PubMed  CAS  Google Scholar 

Awata T, Shimada A, Maruyama T, et al. Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non- Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S). Diabetes Ther. 2017;8:1123–34.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: a one year prospective study. J Clin Endocrinol Metab. 2014;99:E876-880.

Article  PubMed  CAS  Google Scholar 

Kim SJ, Nian C, McIntosh CH. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration. Diabetes. 2010;59:1739–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tian L, Gao J, Hao J, et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidylpeptidase IV inhibitor. Endocrinology. 2010;151:3049–60.

Article  PubMed  CAS  Google Scholar 

Shimada A, Shigihara T, Okubo Y, et al. Pioglitazone may accelerate the disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev. 2011;27:951–3.

Article  PubMed  CAS  Google Scholar 

Ursini F, Russo E, Pellino G, et al. Metformin and Autoimmunity: A “New Deal” of an Old Drug. Front Immunol. 2018;9:1236.

Article  PubMed  PubMed Central  Google Scholar 

Maganti AV, Tersey SA, Syed F, et al. Peroxisome Proliferator-activated Receptor-γ Activation Augments the β-Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β-Cell Death in Non-obese Diabetic Mice. J Biol Chem. 2016;291(43):22524–33.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shigihara T, Okubo Y, Kanazawa Y, et al. Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes. Ann N Y Acad Sci. 2006;1079:365–8.

Article  PubMed  CAS  Google Scholar 

Zhou Z, Li X, Huang G, et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev. 2005;21:203–8.

Article  PubMed  Google Scholar 

Pozzilli P, Leslie RD, Peters AL, et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 Trials. Diabetes Obes Metab. 2018;20:1490–8.

Article  PubMed  CAS  Google Scholar 

Shimada A, Kawasaki E, Abiru N, et al. Statement regarding treatment for suspected slowly progressive type 1 diabetes cases. J Japan Diabetes Soc. 2023;66:807–14 ((In Japanese)).

Google Scholar